Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1651 - Comparison of pharmacokinetic (PK) profiles of netupitant (NETU) and palonosetron (PALO) in Chinese and Caucasian healthy volunteers (HV) (514P)

Date

18 Nov 2017

Session

Poster lunch

Topics

Supportive Care and Symptom Management;  Clinical Research

Presenters

Matti Aapro

Citation

Annals of Oncology (2017) 28 (suppl_10): x155-x165. 10.1093/annonc/mdx676

Authors

M. Aapro1, A. Bernareggi2

Author affiliations

  • 1 Multidisciplinary Oncology Institute, Clinique de Genolier, 1272 - Genolier/CH
  • 2 R & D Innovation And Strategy, Helsinn Healthcare SA, 6912 - Lugano/CH
More

Resources

Abstract 1651

Background

NEPA, a fixed oral combination of NETU (neurokinin-1 receptor antagonist [NK1 RA]) and PALO (5-hydroxytryptamine-3 [5-HT3] RA), has been studied in > 1150 patients in phase 2/3 trials (with 83% of patients being Caucasian). NEPA has shown higher efficacy over PALO in preventing CINV associated with cisplatin and AC chemotherapy, and a good safety profile. In a recent Asian registration phase 3 trial, with patient eligibility criteria similar to those of pivotal trials in Caucasians, an oral dose of NEPA was found to be noninferior to a 3-day oral aprepitant/granisetron regimen in CINV prevention. This presentation discusses PK behaviors of NETU and PALO in Chinese and Caucasian HV.

Methods

Results from one phase 1 trial in 18 Chinese HV and five phase 1 trials in Caucasian HV (NETU, N = 232; PALO, N = 205) were analyzed. HV received an oral dose of NEPA (NETU 300 mg/PALO 0.5 mg), and NETU and PALO plasma concentrations were determined by liquid chromatography-tandem mass spectrometry. PK parameters were estimated from plasma concentration-time curves by noncompartmental analysis using WinNonlin v6.3 software (Certara USA, Inc.).

Results

The PK profiles of NETU and PALO for Chinese and Caucasian HV are shown (Table). Mean body weight (BW) of Chinese HV was 15–19% lower than that of Caucasians, as expected. The PK profile of NETU was comparable between Chinese and Caucasian HV. For PALO, mean Cmax and overall exposure were higher in Chinese HV. The lower mean BW and higher incidence of nonfunctional CYP2D6 alleles (main enzyme responsible for the metabolism of PALO) in Chinese could be postulated to explain these differences.

Conclusions

The similar efficacy and safety of PALO and NEPA in pivotal trials in both populations suggest that some PK differences between Chinese and Caucasian are probably unlikely to affect the clinical outcome.

Clinical trial identification

Not applicable

Legal entity responsible for the study

Helsinn Healthcare SA

Funding

Helsinn Healthcare SA

Disclosure

M. Aapro: Advisor for Eisai, Helsinn, Merck, Mundipharma, Roche, and Tesaro; honoraria from Eisai, Helsinn, Merck, Mundipharma, Roche, and Tesaro; and has received grants from Helsinn, Merck, Roche, and Tesaro. A. Bernareggi: Employee of Helsinn Healthcare SA.Table: 514P

Netupitant and palonosetron PK parameters in Chinese and Caucasian healthy volunteers

Study population (N, mean BW)Netupitant dose (mg)Netupitant PK parameters, mean (CV%)
Cmax (ng/mL)tmax (h)AUCinf (ng·h/mL)t1/2 (h)
Chinese (18, 62.9 kg)300698 (31.1)4.36 (14.6)22000 (20.0)73.1 (37.1)
Caucasian (232, 74.2 kg)300Range of mean (CV%) values
374 (37.1) – 650 (21.8)5.01 (35.4) – 5.66 (17.1)13303 (34.5) – 22391 (38.6)76.6 (37.6) – 101.2 (52.2)
Study population (N, mean BW)Palonosetron dose (mg)Palonosetron PK parameters, mean (CV%)
Cmax (ng/L)tmax (h)AUCinf (ng·h/L)t1/2 (h)
Chinese (18, 62.9 kg)0.51800 (14.0)3.25 (43.3)81000 (17.3)45.1 (25.0)
Caucasian (205, 73.4 kg)0.5Range of mean (CV%) values
768 (20.7) – 1530 (25.6)3.76 (40.6) – 4.96 (24.3)33199 (20.9) – 56710 (32.8)36.9 (23.6) – 48.3 (46.7)

AUCinf, area under the plasma concentration-time curve from time 0 to infinity; BW, body weight; Cmax, maximum plasma concentration; CV, coefficient of variation; t1/2, plasma half-life; tmax, time to Cmax.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.